 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Eliem Therapeutics, Inc. (ELYM) and Encourages Investors to Contact the Firm SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation...

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Eliem Therapeutics, Inc. (ELYM) and Encourages Investors to Contact the Firm

Kuehn Law Encourages ALPN, JBT, ELYM, and HRT Investors to Contact Law Firm Kuehn Law Encourages ALPN, JBT, ELYM, and HRT Investors to Contact Law Firm PR Newswire NEW YORK, April 11, 2024 NEW YORK...

Kuehn Law Encourages ALPN, JBT, ELYM, and HRT Investors to Contact Law Firm

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALPN, ELYM, MODN SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALPN, ELYM, MODN PR Newswire NEW YORK, April 11, 2024 NEW YORK...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALPN, ELYM, MODN

Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Eliem Therapeutics, Inc. (NASDAQ: ELYM) and Tenet Medicines, Inc. is fair to Eliem shareholders. Halper Sadeh...

ELYM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Eliem Therapeutics, Inc. Is Fair to Shareholders

Eliem Therapeutics, Inc. (NASDAQ:ELYM - Get Free Report) was the recipient of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 13,000...

Eliem Therapeutics, Inc. (NASDAQ:ELYM) Sees Large Growth in Short Interest

Shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM  Get Free Report) traded up 3.5% during trading on Friday . The company traded as high as $2.65 and last traded at $2.65. 270 shares were traded...

Eliem Therapeutics (NASDAQ:ELYM) Stock Price Up 3.5%

Eliem Therapeutics, Inc. (NASDAQ:ELYM  Get Free Report)s stock price traded up 3.5% on Friday . The stock traded as high as $2.65 and last traded at $2.65. 270 shares were traded during...

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Here's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Situation

Eliem Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Its clinical-stage candidates are ETX-810 and ETX-155. ETX-810 is a novel palmitoylethanolamide (PEA) prodrug initially being developed for the treatment of diabetic peripheral neuropathic pain (DPNP) and pain associated with lumbosacral radiculopathy. ETX-155 is a neurosteroid GABAA receptor positive allosteric modulator (PAM) initially being developed for major depressive disorder (MDD), perimenopausal depression (PMD) and focal onset seizures. The company was founded by Andrew D. Levin and Valerie Morisset on October 18, 2018 and is headquartered in Wilmington, DE.

Volume (M)	217,701.00
52-Wk High	$5.19
52-Wk Low	$2.34

ELYM Eliem Therapeutics Inc

About

Feed

News

Earnings

Fundamentals